Abstract. Oldhamianoside II is a novel triterpenoidsaponin that can be isolated from the roots of Gypsophila oldhamiana. In vitro and in vivo experiments have revealed that it inhibits tumor growth and metastasis in various types of tumor; however, the exact mechanism remains to be fully elucidated. In the present study, oldhamianoside II treatment in prostate cancer cells exerted substantial anticancer activity, including decreased cell proliferation and invasion. Mechanistically, oldhamianoside II was found to reverse the epithelial-mesenchymal transition (EMT), as demonstrated by its induction of E-cadherin and suppression of vimentin and N-cadherin at the mRNA and protein levels. Furthermore, oldhamianoside II treatment upregulated Wnt antagonist expression and promoted the proteasome-mediated degradation of β-catenin to inhibit the activity of β-catenin signaling. In summary, the present study revealed that oldhamianoside II exerts its antitumor effects via the regulation of EMT and β-catenin function, and further supports its potential for use in clinical treatment.
Introduction
Prostate Cancer (PCa) is the second most frequently diagnosed cancer among men and the fifth leading cause of cancer mortalities worldwide (1) . Mortality rates for PCa have been decreasing in the majority of more developed countries, but continue to rise in certain Asian countries, particularly in China (1) . The primary diagnostic tools used to obtain evidence of PCa include digital rectal examination, serum concentration of PSA and transrectal ultrasound guided biopsies (2) . Diagnosis depends on the presence of adenocarcinoma in operative specimens and prostate biopsy cores (2) . The factors driving the increase of incidence in prostate cancer are not entirely understood; however, they may include gradual implementation of prostate-specific antigen screening and improved biopsy techniques, or the effect of an increasingly westernized lifestyle, in particular dietary habits (1) . Despite recent hormonal therapies exhibiting a survival advantage during treatment with inhibitors, including abiraterone acetate (17α-hydroxylase inhibitor) and enzalutamide (androgen receptor inhibitor), the median duration of response is <1 year (2) . Furthermore, the treatment options for recurrent and metastatic PCa are limited and predominantly palliative (2) .
Epithelial-mesenchymal transition (EMT) is an early embryonic development program, in which cells convert from the epithelial to the mesenchymal state (3) . During this process, the epithelial cells acquire mesenchymal cell morphology through the suppressing the epithelial markers and inducing mesenchymal markers (4) . It has been shown to have a critical role during prostate cancer progression and metastasis (5) . Another important signaling pathway is Wingless (WNT)/β-catenin (6) and activation of Wnt/β-catenin signaling induces motility, invasiveness, cell-fate decisions and the maintenance of self-renewal potential (7 Oldhamianoside II, atriterpenoidsaponin, may be isolated from Gypsophila oldhamiana, a plant that is rich in saponins (9) . A previous study demonstrated that oldhamianoside II was able to effectively inhibit the proliferation and migration of tumor cells, as well as tumor angiogenesis (10) . These results indicated the feasibility of oldhamianoside II for further clinical application. A previous study demonstrated that oldhamianoside II exerted antitumor activity via inhibition of C-X-C motif chemokine receptor 4, matrix metalloproteinase 2, phosphoinositide 3-kinase/protein kinase B and extracellular signal-related kinase/mitogen activated protein kinase (10); however, the specific mechanisms underlying the antitumor effects of oldhamianoside II in PCa remain unclear. The present study aimed to further elucidate these mechanisms, and revealed that oldhamianoside II inhibited the proliferation and invasion of PCa cells by regulating the process of epithelial-mesenchymal transition (EMT) and the activity of the Wnt/β-catenin signaling pathway.
Materials and methods
Cell culture and treatment. VCaP and PC3 human PCa cell lines were purchased from American Type Culture Collection (Manassas, VA, USA) and maintained in Dulbecco's modified Eagle's medium (HyClone; GE Healthcare, Chicago, IL, USA) or RPMI-1640 (HyClone; GE Healthcare) supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). For the experiments, cells were cultured at 37˚C and stimulated with oldhamianoside II, which was extracted and isolated as previously described (9) . Cycloheximide (50 µg/ml, CHX; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) or MG132 (30 µM, Sigma-Aldrich; Merck KGaA) were applied to stimulate PCa cells for 6h before oldhamianoside II treatment.
MTT assay. An MTT assay was performed to detect to the cell viability as previously described (11) . Briefly, 1x10 4 cells per well in 200 µl medium were seeded into a 96-well plate and then subjected to the indicated treatments for 24-72 h at 37˚C. For detection, 20 µl MTT was added to each well and incubated for 4 h. Subsequently, the cultured medium was discarded and 150 µl dimethyl sulfoxide was added. The absorbance was then determined at 490 nm, and all experiments were performed in triplicate.
Migration assay. For the migration assay, 1x10
4 cells per well in serum-free medium were plated into 24-well Transwell chambers with polycarbonate filter inserts (pore size, 8.0-10.0 µm; Corning Incorporated, Corning, NY, USA). The lower chambers contained normal growth medium with 10% fetal bovine serum. Following incubation at 37˚C for 24 h, the cells in the upper compartment were removed and the migrated cells were fixed and stained using the crystal violet method. Cells were quantified in five randomly selected microscopic fields using light microscope (magnification, x200) and all experiments were performed in triplicate.
RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA was extracted using an RNeasy Mini kit (Qiagen), and RNA (1 µg) was reverse-transcribed to cDNA using a SuperScript II cDNA synthesis kit (Invitrogen). Subsequently, 1 µg of cDNA product was used for amplification with the PCR amplification kit (Takara) as previously described (12) . The details of the primers for each human gene were as follows: E-cadherin forward, 5'-TCA TGA GTG TCC CCC GGT AT-3', and reverse, 5'-TCT TGA AGC GAT TGC CCC AT-3'; N-cadherin forward, 5'-CGC CAT CCG CTC CAC TT-3', and reverse, 5'-GCT GAT GAC AAA TAG CGG GC-3'; vimentin forward, 5'-GGA CCA GCT AAC CAA CGA CA-3', and reverse, 5'-AAG GTC AAG ACG TGC CAG AG-3'; cyclin D1 (CCND1) forward, 5'-CAC ACG GAC TAC AGG GGA GT-3', and reverse, 5'-GAT GGT TTC CAC TTC GCA GC-3'; c-JUN forward, 5'-GTG CCG AAA AAG GAA GCT GG-3', and reverse, 5'-CTG CGT TAG CAT GAG TTG GC-3'; axin 2 (AXIN2) forward, 5'-AAA CGC AAT GGG AAA GGC AC-3', and reverse, 5'-TGT GCT TTG GGC ACT ATG GG-3'; Dickkopf-1 (DKK1) forward, 5'-AAG TGT GGT GGC TTC CAA GG-3', and reverse, 5'-CCG GCC ACA TGA GTA AGA GG-3'; protein phosphatase 2 catalytic subunit β (PPP2CB) forward, 5'-ACC ATG CCA ATG GTC TCA CA-3', and reverse, 5'-AAC ATG AGG CTC ACC ACG AC-3'; secreted frizzled-related protein 5 (SFRP5) forward, 5'-CAC TCG GAT ACG CAG GTC TT-3' , and reverse, 5'-CAC TCG GAT ACG CAG GTC TT-3'; and GAPDH (internal loading control) forward, 5'-AAT GGG CAG CCG TTA GGA AA-3', and reverse, 5'-GCG CCC AAT ACG ACC AAA TC-3'. The reaction was performed at 94˚C for 30 sec, 56˚C for 30 sec and 72˚C for 30 sec, for 36 cycles. GAPDH served as the loading control. Analysis of relative gene expression data using real-time quantitative PCR and the 2 -ΔΔCq method (13) . All reactions were performed in triplicate.
Western blot analysis. The nuclear proteins were extracted using Nuclear and Cytoplasmic Extraction Reagents kits (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Western blotting was performed as previously described (14) . The primary antibodies against E-cadherin (1:1,000; cat no. 3195), N-cadherin (1:1,000; cat no. 13116), β-catenin (1:1,000; cat no. 8480) and Vimentin (1:1,000; cat no. 5741) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA) and the antibodies against cyclin D1 (1:1,000; cat no. ab134175), c-Jun (1:1,000; cat no. ab32137) and Lamin A (1:1,000; cat no. ab108922) were purchased from Abcam (Cambridge, UK). For the loading control, HRP-conjugated-GAPDH antibodies (1:1,000; cat no. sc-293335; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) were used. The primary antibodies were incubated at 4˚C overnight, and the second antibody labeled with horseradish-peroxidase was subsequently incubated at 37˚C for 1 h. SuperSignal West Pico kit (Thermo Fisher Scientific, Inc.) was used to visualize the protein bands.
Statistical analysis. Statistical analyses of the data were performed using SPSS version 16 (SPSS, Inc., Chicago, IL, USA). Data are presented as the mean ± standard deviation and were analyzed by one-way analysis of variance followed by Tukey's post hoc test, considering oldhamianoside II treatment and cell viability at each time point, or vehicle and oldhamianoside II treatment at different concentrations. P<0.05 was considered to indicate a statistically significant difference.
Results
Oldhamianoside II inhibits the proliferation and invasion of PCa cell lines. VCaP and PC3 human PCa cell lines were treated to detect the effects of oldhamianoside II on the biological activity of tumor cells. Consistently with a previous study (10) , the MTT analysis demonstrated that oldhamianoside II treatment at various concentrations decreased the viability of PC3 and VCaP cells (Fig. 1A and B) . In addition, a Transwell migration assay demonstrated that 50 µg/l oldhamianoside II significantly inhibited the migration ability of PC3 (Fig. 1C) and VCaP cells (Fig. 1D) . Oldhamianoside II inhibits EMT in VCaP cells. EMT is associated with the metastasis and progression of PCa (15) . As presented in Fig. 2A , treatment with 50 and 100 µg/l oldhamianoside II in VCaP cells for 72 h suppressed EMT, as indicated by the suppression of N-cadherin ( Fig. 2A) and Vimentin (Fig. 2B ) and the induction of E-cadherin (Fig. 2C) at the mRNA level. Furthermore, following the treatment of VCaP cells with oldhamianoside II at 50 and 100 µg/l for 48 h, western blot analysis demonstrated that the level of E-cadherin protein was significantly elevated, whereas the levels of Vimentin and N-cadherin were decreased significantly (Fig. 2D) .
Oldhamianoside II inhibits the expression and activity of β-catenin in PCa cells. Based on the aforementioned results, the present study investigated whether oldhamianoside II was able to regulate the activity of the Wnt/β-catenin signaling pathway in PCa cells. Therefore, VCaP cells were treated with oldhamianoside II and the level of β-catenin was determined by western blotting. The total β-catenin protein level (Fig. 3A) and its nuclear content (Fig. 3B) were significantly suppressed in VCaP cells following oldhamianoside II treatment at 50 and 100 µg/l. Subsequently, the expression levels of the target genes of β-catenin, CCND1 and c-JUN were also evaluated in response to oldhamianoside II treatment (16, 17) . As shown in Fig. 3C -F, oldhamianoside II treatment induced a significant decrease in the expression levels of these target genes at the mRNA (Fig. 3C and E) and protein ( Fig. 3D and F) levels. As β-catenin is well-validated to be targeted for ubiquitin-mediated proteolysis (18), we subsequently investigated whether oldhamianoside II was able to regulate the proteolysis of β-catenin. As presented in Fig. 3G , the effect of oldhamianoside II on β-catenin and its target cyclin D1 was blocked in the presence of the proteasome inhibitor MG132, which indicated that oldhamianoside II promoted proteasome-mediated degradation of β-catenin. Consistently, oldhamianoside II treatment resulted in a significant decrease in the half-life of β-catenin (Fig. 3H) .
Oldhamianoside II promotes β-catenin degradation by inducing expression of Wnt antagonists.
A previous study demonstrated that antagonists of the Wnt signaling pathway promoted β-catenin degradation by interfering with the binding of Wnt proteins to their receptors or organizing the destruction complex (19) . To further confirm the regulation of oldhamianoside II on the Wnt/β-catenin signaling pathway, the expression level of natural inhibitors towards Wnt signaling were detected following oldhamianoside II treatment. Four well-characterized antagonists (AXIN2, PPP2CB, DKK1 and SFRP5) targeting Wnt/β-catenin signaling (20) were selected for investigation, and the results revealed that AXIN2 (Fig. 4A), PPP2CB (Fig. 4B) , DKK1 (Fig. 4C) and SFRP5 (Fig. 4D) were upregulated significantly in oldhamianoside II-treated cells.
Discussion
Oldhamianoside II, a novel triterpenoidsaponin, was first chemically isolated from Gypsophila oldhamiana, commonly called ʻXia Cao' in China (9); it contains a triterpenoidaglycone and eight sugar chains. A previous study demonstrated that oldhamianoside II may inhibit tumor growth and angiogenesis, and that the migration of tumor cells was also suppressed following oldhamianoside II treatment (10) . Consistent with previous evidence, the present study demonstrated that oldhamianoside II inhibited the proliferation and invasion of PCa cells.
EMT progression is characterized by cytoskeletal reorganization, followed by the suppression of cell adhesion, finally leading to enhanced cell motility. Numerous studies have validated that EMT is closely associated with tumor progression and metastasis (21) . In the present study, by characterizing the expression level of epithelial and mesenchymal markers, it was demonstrated that oldhamianoside II inhibited EMT in PCa cells. Together, the aforementioned results corroborate the inhibitory role of oldhamianoside II during PCa progression.
Aberrantly activated Wnt/β-catenin signaling may induce tumor formation and progression (22) . β-catenin is a transcription factor that is involved in the Wnt signaling pathway and serves an important role in oncogenesis in combination with T-cell factor (Tcf) and protein kinase D1 (23, 24) . It has previously been reported that β-catenin was dysregulated in and associated with the development of numerous types of cancer, including PCa (25) , and that the shuttle between the cytoplasm and nucleus was pivotal for its pro-or antitumor functions (26) . Therefore, a study focusing on the regulation of β-catenin would highlight the pathological mechanism underlying PCa and also provide novel treatment targets. The results of the present study revealed that oldhamianoside II decreased the expression level of β-catenin and its downstream target genes, CCND1 and c-Jun, resulting in the suppression of PCa growth. Notably, oldhamianoside II was able to promote the proteasome-mediated degradation of β-catenin. These results further supported the potential application of oldhamianoside II in the treatment of PCa.
Wnt/β-catenin signaling is frequently activated due to the suppression of its antagonists (27) . To further investigate the mechanism underlying the effects of oldhamianoside II on Wnt/β-catenin signaling, the present study also detected the expression levels of Wnt antagonists, including AXIN2, PPP22B, DKK1 and SFRP5 (28) . Oldhamianoside II treatment was found to induce the expression of these genes. A previous study demonstrated that antagonists of the Wnt signaling pathway inhibited its activity in various ways; among these, DKK1 inhibited the interaction between the receptor and its ligand (29) , while AXIN2 and PPP2CB could form a destruction complex to degrade β-catenin (30) . Together with the present study, these findings suggest that oldhamianoside II may inhibit PCa progression via targeting β-catenin through various mechanisms.
In conclusion, the present study demonstrated a novel molecular mechanism, involving the reversal of EMT and inhibition of β-catenin signaling, through which the anticancer effects of oldhamianoside II are mediated. Oldhamianoside II may act as a chemopreventive agent to inhibit or delay the progression of PCa by promoting β-catenin degradation and inhibiting its transcriptional activity. The potential clinical application of oldhamianoside II in PCa treatment requires further study.
